Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab plus nivolumab in pediatric and young adult recurrent or refractory Hodgkin and non-Hodgkin lymphoma
NL-OMON53587Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of relatlimab and nivolumab in classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-limiting toxicities, maximum tolerated dose/recommended phase 2 dose, and safety, Relatlimab pharmacokinetics and 1 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
relatlimabnivolumab
03
Conditions
classical Hodgkin lymphoma (cHL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON53587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53587.